What Happened?

Shares of healthcare services company Agilon Health (NYSE: AGL) jumped 16.4% in the morning session after the company reported decent third-quarter results that beat revenue expectations but fell significantly short on profitability. 

The healthcare services company posted revenue of $1.44 billion, marking a 1.1% decline year over year but narrowly surpassing analyst estimates. However, the bottom line painted a different picture, with a GAAP loss of $0.27 per share, missing the consensus estimate of a $0.17 loss. Guidance for the full year was also mixed; while the revenue forecast was in line with expectations, the outlook for full-year adjusted EBITDA was well below analyst projections. Despite the significant profitability miss, investors appeared to focus on the top-line beat and stable revenue guidance, sending the shares higher.

After the initial pop the shares cooled down to $0.76, up 4.8% from previous close.

Is now the time to buy agilon health? Access our full analysis report here.

What Is The Market Telling Us

agilon health’s shares are extremely volatile and have had 77 moves greater than 5% over the last year. But moves this big are rare even for agilon health and indicate this news significantly impacted the market’s perception of the business.

The previous big move we wrote about was 26 days ago when the stock dropped 5.3% on the news that worries over worsening trade relations with China were triggered by critical comments from President Donald Trump. The president's tone and the suggestion of canceling a meeting with President Xi caused a rapid sell-off in the market. The trade dispute flared up after China imposed export controls on rare earth minerals, which are critical components for high-tech manufacturing. The escalation of the trade war raises concerns about supply chain disruptions and increased costs for technology companies, which are heavily reliant on global trade, leading to a broad sell-off in the sector.

agilon health is down 60.5% since the beginning of the year, and at $0.76 per share, it is trading 86.6% below its 52-week high of $5.68 from April 2025. Investors who bought $1,000 worth of agilon health’s shares at the IPO in April 2021 would now be looking at an investment worth $24.47.

While Wall Street chases Nvidia at all-time highs, an under-the-radar semiconductor supplier is dominating a critical AI component these giants can’t build without. Click here to access our full research report.